Bicara Therapeutics Inc. Announces Executive Changes

Published: 2026-05-11 15:35:25 ET BCAX

Published on 05/11/2026 at 03:35 pm EDT

Bicara Therapeutics Inc. announced that effective May 8, 2026, Bill Schelman, M.D., Ph.D., previously the company?s Executive Vice President, Clinical Development, has succeeded David Raben, M.D., as Chief Medical Officer, and Dr. Raben has transitioned to serve as a Senior Executive Advisor. With this promotion, Dr. Schelman is responsible for medical affairs and clinical development. In his new role, Dr. Raben will advise on clinical development strategy across the company?s portfolio.

Announced that effective May 8, 2026, Chris Sarchi was appointed as Chief Commercial Officer. In this role, he will lead the commercial organization in preparation for launch readiness.